Abstract
BackgroundThere is evidence that xanthine oxidase inhibitors (XOI) may reduce the risk of major adverse cardiovascular events (MACE) (1,2) and lower blood pressure (3). To date, this evidence is based...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
